Table 3 Efficacy of mobilization with plerixafor plus G-CSF
Myeloma | Lymphoma | All cases | |
|---|---|---|---|
PB CD34+ levels (cells per μL) | |||
Before plerixafor | |||
Patients tested N (%) | 17 (53) | 13 (54) | 30 (54) |
Median | 4.9 | 3.3 | 3.6 |
Min–Max | 1.1–13.0 | 1.2–9.8 | 1.1–13.0 |
Mean (s.d.) | 4.5 (3.6) | 3.9 (2.7) | 4.2 (3.1) |
After plerixafor | |||
Patients tested, N (%) | 22 (69) | 19 (79) | 41 (73) |
Median | 18.7 | 17.0 | 17.9 |
Min–Max | 2.8–192.0 | 2.9–35.9 | 2.8–192.2 |
Mean (s.d.) | 30.8 (41.9) | 17.4 (9.7) | 24.9 (32.4) |
Patients reaching ⩾10 N (%) | 16 (73) | 13 (68) | 29 (71) |
Fold-increase with plerixafor | |||
Patients tested, N (%) | 17 (53) | 13 (54) | 30 (54) |
Median | 4.6 | 5.9 | 4.9 |
Min–Max | 0.6–38.4 | 1.5–13.3 | 0.6–38.4 |
Mean (s.d.) | 9.4 (12.1) | 6.3 (3.8) | 7.6 (8.3) |
Apheresis procedures | |||
Median | 2 | 2 | 2 |
Min–Max | 1–4 | 0–4 | 0–4 |
Mean (s.d.) | 2.0 (0.8) | 1.75 (0.9) | 1.9 (0.8) |
CD34+ PBSCs collected ( × 10 6 per kg) | |||
Median | 2.8 | 2.3 | 2.6 |
Min–Max | 0.4–10.6 | 1.1–4.6 | 0.4–10.6 |
Mean (s.d.) | 3.4 (2.1) | 2.5 (0.9) | 3.0 (1.7) |
Patients collecting ⩾2 N (%) | 27 (84) | 15 (63) | 42 (75) |
